Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;3(2):129-38.
doi: 10.3233/PRM-2010-0117.

Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI

Tamara Alliston  1
Affiliations

Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI

Tamara Alliston. J Pediatr Rehabil Med. 2010.

Abstract

Mucopolysaccharidosis type VI (MPS VI), also called Maroteaux-Lamy syndrome, is an autosomal recessive lysosomal storage disorder caused by deficiency of a specific enzyme required for glycosaminoglycan catabolism. Deficiency in the N-acetylgalactosamine-4-sulfatase (4S) enzyme, also called arylsulfatase B (ARSB), may have profound skeletal consequences. In MPS VI, partially degraded glycosaminoglycans (GAGs) such as dermatan sulfate and chondroitin sulfate accumulate within lysosomes. Through mechanisms that remain unclear, the abnormal GAG metabolism impacts several aspects of cellular function, particularly in the growth plate. This article explores the hypothesis that accrued partially degraded GAGs may contribute to deregulation of signaling pathways that normally orchestrate skeletal development, with a focus on members of the transforming growth factor-β (TGF-β) family. Understanding the molecular mechanisms disrupted by MPS VI may yield insight to improve the efficacy of MPS VI therapies, including bone marrow transplantation and enzyme replacement therapies.

Keywords: MPS VI; TGF-β; chondroitin sulfate; growth plate; osteoblast and chondrocyte differentiation.

PubMed Disclaimer

References

    1. Abreu S, et al. Growth plate pathology in feline mucopolysaccharidosis VI. Calcif Tissue Int. 1995;57(3):185–190. - PubMed
    1. Alliston T, Piek E, Derynck R. TGF-β family signaling in sketetal development, maintenance, and disease. In: Derynck R, Miyazono K, editors. The TGF-β Family. Cold Spring Harbor Press; Woodbury, NY: 2008. pp. 667–723.
    1. Alliston T, et al. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001;20(9):2254–2272. - PMC - PubMed
    1. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116(Pt 2):217–224. - PubMed
    1. Balooch G, et al. TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA. 2005;102(52):18813–18818. - PMC - PubMed

LinkOut - more resources